Advertisement

Reactions Weekly

, Volume 1697, Issue 1, pp 214–214 | Cite as

Ipilimumab/pembrolizumab

Various toxicities: 3 case reports
Case report
  • 19 Downloads

Reference

  1. Scott ES, et al. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. European Journal of Endocrinology 178: 173-180, No. 2, Feb 2018. Available from: URL: http://doi.org/10.1530/EJE-17-0810 - AustraliaCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations